Skip to main content
Fig. 10 | BMC Pulmonary Medicine

Fig. 10

From: Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study

Fig. 10

a Nausea (reported incidence: 36%). b Rash (reported incidence: 30%). c Abdominal pain (reported incidence: 24%); includes upper abdominal pain, abdominal distension, and stomach discomfort. d Upper respiratory tract infection (reported incidence: 27%). e Diarrhoea (reported incidence: 26%). f Fatigue (reported incidence: 26%). g Dyspepsia (reported incidence: 19%). h Dizziness (reported incidence: 18%). i Vomiting (reported incidence: 13%). j Anorexia (reported incidence: 13%). k Gastroesophageal Reflux Disease (reported incidence: 11%). l Insomnia (reported incidence: 10%). m Weight decreased (reported incidence: 10%). n Arthralgia (reported incidence: 10%). Statements with a consensus for are bolded; statements with consensus against are shown with a grey background

Back to article page